Richard Carvajal is an Oncology physician. ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
177 Fort Washington Ave
New York, NY 100323733
Telephone
212-305-6514Registry record last updated 13 Jun 2016.
Clinical trials
- Adjuvant Tebentafusp in High Risk Ocular Melanoma
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Sponsor: Columbia University
- Epacadostat and Pembrolizumab in Patients With GIST
Sponsor: Columbia University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- HISTOSONICS, INC.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
2 NIH research awards on record, funded 2008–2021 per NIH RePORTER. The latest:
- Exploratory clinical trial of topical Imiquimod 5% cream as window-of-opportunity monotherapy for early-stage oral cancer
Columbia University Health Sciences
FY2021$126,755R21CA252441 - Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
Sloan-Kettering Inst Can Research
FY2009$426,600R21CA133866 - Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
Sloan-Kettering Inst Can Research
FY2008$426,881R21CA133866
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”